Nina Kukar, MD
Cardiovascular Disease · New York, NYNPI 1174768980
Payments from drug & device makers
Across 82 payments — averaging $484.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$38K
- Heartflow, Inc.$684
- Abbott$465
- AstraZeneca$175
- Boehringer Ingelheim$156
- Esperion Therapeutics, Inc.$149
- plus $569 from 11 others
What the payments were for
- Consulting fees$3,5759%
- Speaking & faculty fees$31,43579%
- Travel & lodging$5381%
- Food & beverage$4,19911%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 40 | $37,558 |
| Heartflow, Inc. | 9 | $684 |
| Abbott | 4 | $465 |
| AstraZeneca | 4 | $175 |
| Boehringer Ingelheim | 3 | $156 |
| Esperion Therapeutics, Inc. | 1 | $149 |
| Biotronik Inc. | 1 | $101 |
| Merck | 3 | $78 |
| Lantheus Medical Imaging, Inc. | 3 | $71 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $67 |
| Lexicon Pharmaceuticals, Inc. | 3 | $60 |
| Alnylam Pharmaceuticals Inc. | 2 | $53 |
| Bridgebio Pharma, Inc. | 2 | $50 |
| Endotronix, Inc. | 1 | $31 |
| Abiomed | 1 | $23 |
| Bayer | 1 | $18 |
| Philips North America LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$37,330
- FFRct$587
- Mitra Clip system$306
- NEXLIZET$149
- NEXLETOL$149
- MitraClip System$139
- BRILINTA$129
- JARDIANCE$125
How this compares
$39,757 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 79 | $50,220 |
| Praluent PenAlirocumab | 21 | $13,725 |
| Ranolazine ErRanolazine | 14 | $1,094 |
| Ezetimibe | 32 | $430 |
| Losartan Potassium | 38 | $409 |
| Metoprolol Succinate | 15 | $356 |
| Labetalol Hcl | 24 | $307 |
| Lisinopril | 16 | $273 |
| Atorvastatin Calcium | 31 | $269 |
| Carvedilol | 15 | $182 |
| Spironolactone | 11 | $156 |
| Amlodipine Besylate | 24 | $119 |
| Metoprolol Tartrate | 16 | $9 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in New York
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Gregg StoneNew York$3.7M
- Valentin FusterNew York$2.9M
- Tamim NazifNew York$2.2M
- Howard WeintraubNew York$1.7M
- Anuradha Lala-TrindadeNew York$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.